Omnicell (OMCL) Tops Q4 EPS by 24c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Omnicell Announces Fiscal Year and Fourth Quarter 2022 Results
February 28, 2023 4:01 PM EST2022 Total Bookings of $1.054 billion
Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion
Ended Year with Over 150 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems
Year End 2022 Backlog of $1.215 billion
Chief Financial Officer to Step Down effective July 1, 2023
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results... More
